ANL Adlai Nortye Ltd. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ANL Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$7.95
Analyst Target
$31.0
+289.9%
Upside
52W High
$12.09
52W Low
$0.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$293.36M
P/E
N/A
ROE
-139.0%
Profit margin
N/A
Debt/Equity
5.63
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
92%
Analysis Accuracy
ANL's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme operational weakness, while the absence of an Altman Z-Score raises significant bankruptcy risk. The company exhibits negative profitability across all metrics, including a ROE of -138.98% and a debt/equity ratio of 5.63, signaling high leverage and poor capital efficiency. Despite a recent 1Y return of +247.2%, this surge is likely speculative, driven by momentum rather than fundamentals. The lack of earnings, cash flow, and dividend data further undermines investor confidence. The stock trades at a price/book of 36.98, indicating a massive premium unsupported by underlying value.
Key Strengths
Recent 1-year price appreciation of +247.2% suggests strong short-term market momentum
Analyst target price of $31.00 implies significant upside potential if fundamentals improve
Low float and small market cap ($0.29B) may attract speculative interest
1-year return outperforms several peers despite negative fundamentals
Insider sentiment at 40/100 suggests some level of internal confidence
Key Risks
Piotroski F-Score of 1/9 indicates severe financial distress and operational failure
Negative ROE (-138.98%) and ROA (-29.81%) reflect deep profitability issues
Debt/Equity ratio of 5.63 is extremely high, indicating unsustainable leverage
No positive cash flow or earnings data, with forward P/E of -31.18 suggesting continued losses
Price/Book of 36.98 is extremely high relative to fundamentals, indicating overvaluation
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
26
Weak
20
55
40
15
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score, Negative profitability and cash flow, High leverage and poor liquidity, Speculative price surge without earnings support
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Analyst target price of $31.00 implies high growth expectations
Watchpoints
- Price/Book of 36.98 is extremely high
- No Graham Number or intrinsic value available
- Forward P/E of -31.18 indicates continued losses
- No positive valuation metrics
Future
55/100
Ref Growth rates
Positives
- Analyst target price suggests strong growth potential
- Recent 6M return of +345.4% indicates speculative momentum
Watchpoints
- No revenue or earnings growth data available
- Negative ROIC and profitability metrics suggest poor future prospects
- High debt burden may constrain future investment
Past
40/100
Ref Historical trends
Positives
- 1-year return of +247.2% shows strong price recovery
Watchpoints
- 5-year change of -47.0% reflects long-term underperformance
- 52-week low of $0.88 indicates extreme volatility
- Price has been highly volatile, with 1-month drop of -14.4%
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.02 suggests minimal liquidity risk
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- Altman Z-Score not available, raising bankruptcy risk
- Quick ratio of 0.69 indicates weak short-term liquidity
- Debt/Equity of 5.63 is dangerously high
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- Dividend strength is 0/100
- No history or indication of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.95
Analyst Target
$31.0
Upside/Downside
+289.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANL and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
Primary
|
-47.0% | -47.0% | +247.2% | +345.4% | -14.4% | -10.8% |
|
ACIU
AC Immune SA
Peer
|
-62.7% | +31.1% | +31.1% | +24.1% | -0.5% | +8.1% |
|
AMRN
Amarin Corporation plc
Peer
|
-88.3% | -51.5% | +87.1% | +2.2% | +1.5% | +9.1% |
|
ALEC
Alector, Inc.
Peer
|
-88.2% | -66.9% | +53.9% | -20.0% | +14.6% | +10.0% |
|
ABSI
Absci Corporation
Peer
|
-88.9% | +37.0% | -17.6% | -6.3% | -8.1% | +0.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-31.18
PEG Ratio
N/A
P/B Ratio
36.98
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
-21.02
Market Cap
$293.36M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
N/A
Gross Margin
N/A
ROE
-138.98%
ROA
-29.81%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
5.63
High debt
Current Ratio
1.02
Good
Quick Ratio
0.69
Poor
Cash/Share
$0.4
Healthcare Sector Comparison
Comparing ANL against 147 companies in the Healthcare sector
(9 bullish, 56 neutral, 82 bearish)
Return on Equity (ROE)
-138.98%
This Stock
vs
-53.48%
Sector Avg
+159.9%
(Excellent)
Debt to Equity
5.63
This Stock
vs
6.19
Sector Avg
-9.1%
(Lower)
Current Ratio
1.02
This Stock
vs
3.37
Sector Avg
-69.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
BEARISH | $293.36M | - | -139.0% | -% | $7.95 | |
|
ACIU
AC Immune SA
|
BEARISH | $303.31M | - | -74.6% | -% | $3.02 | |
|
AMRN
Amarin Corporation plc
|
BEARISH | $319.13M | - | -8.2% | -18.2% | $15.34 | |
|
ALEC
Alector, Inc.
|
BEARISH | $242.8M | - | -181.6% | -% | $2.2 | |
|
ABSI
Absci Corporation
|
BEARISH | $359.39M | - | -55.7% | -% | $2.39 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
HC Wainwright & Co.
2026-02-13
Neutral
Buy
Past News Coverage
Recent headlines mentioning ANL from our newsroom.
Newest → oldest
No matching news yet.